StreetSmart Live! Presents Frank Holmes’ Virtual Junior Mining Expo on 11/12/2020. Learn More

Sector Expert: Dr. KSS

Dr. KSS is the founder and editor-in-chief of He is an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, he has been investing in biotech companies with great success. Dr. KSS earned his degrees at a top 10 U.S. institution, where he was an NIH scholar and graduated with top honors. He has extensive post-doctoral research experience and am board certified in internal medicine and also gastroenterology. His goal is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities.

Subscribe to
Streetwise Reports

Companies Commented On

  • Acurx Pharmaceuticals LLC

Recent Interviews

With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury (10/19/20)
Brain graph

Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space? (8/10/20)

Dr. KSS, the founder and editor-in-chief of, compares the two drugs as potential treatments for C. difficile.

Ten Good Reasons to Invest Now Pre-Market in Acurx Pharmaceuticals (8/3/20)

Dr. KSS, the founder and editor-in-chief of, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years.

Due to permission requirements, not all quotes are shown.